Home / Publication / A Randomised Study of the Effect of Danoprevir/Ritonavir or Ritonavir on Substrates of Cytochrome P450 (CYP) 3A and 2C9 in Chronic Hepatitis C Patients Using a Drug Cocktail

論文

A Randomised Study of the Effect of Danoprevir/Ritonavir or Ritonavir on Substrates of Cytochrome P450 (CYP) 3A and 2C9 in Chronic Hepatitis C Patients Using a Drug Cocktail

Author(s): Peter Morcos, Linda Change, Rohit Kulkarni, Mylene Giraudon, Nancy Shulman, Barbara Brennan, Patrick Smith, Jonathan Tran

Year: 2013年7月20日

AUC（線形および対数線形）の計算

ブログ

Accumulation: What It Means and How to Calculate It

ブログ

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

ビデオ

Bridging Strategy & Execution: Sophia Fong’s Approach to Drug Development

ビデオ

Powered by Translations.com GlobalLink Web Software

A Randomised Study of the Effect of Danoprevir/Ritonavir or Ritonavir on Substrates of Cytochrome P450 (CYP) 3A and 2C9 in Chronic Hepatitis C Patients Using a Drug Cocktail

A Randomised Study of the Effect of Danoprevir/Ritonavir or Ritonavir on Substrates of Cytochrome P450 (CYP) 3A and 2C9 in Chronic Hepatitis C Patients Using a Drug Cocktail

AUC（線形および対数線形）の計算

Accumulation: What It Means and How to Calculate It

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

Bridging Strategy & Execution: Sophia Fong’s Approach to Drug Development

メルマガ登録

クイックアクセス

ソリューション

お問合せ